18.11.2013 Views

Panel Disdussion

Panel Disdussion

Panel Disdussion

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of<br />

Nuclear Congress Medicine of Nuclear Medicine<br />

Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011<br />

Evaluation of<br />

153 Sm-EDTMP as a therapeutic<br />

radiopharmaceutical for bone pain palliation in clinical test<br />

G.A. Shabani, H.R. Khosrounejad, F. Hajhasan Abbasi, M. Farahani,<br />

M. Goudarzi, Y.H. Tavakoli, M.H. Talebi<br />

Radioisotope research group, NSTRI, Atomic Energy org. of Iran,<br />

Introduction: Owing to its favorable decay characteristic of<br />

153 Sm[t 12 =46.27h, Eβ (max) =810 KeV and Eγ=103KeV] and EDTMP<br />

(Ethylene diamine tetra methylene phosphonate as a ligands, is one<br />

of the most widely used as therapeutic radiopharmaceutical for bone<br />

pain palliation. Also it was approved by FDA in 1997.<br />

Methods: Enriched 152 Sm target was irradiated by thermal neutron<br />

flux in Tehran research reactor then dissolved in acidic media; EDTMP<br />

was dissolved in DDW. After labelling, the QC and RCP were done by<br />

ITLC chromatography.<br />

Results: Radiochemical purity of 153 Sm-EDTMP was more than 98<br />

percent at RT. Biodistribution in rat was the same the other<br />

references.<br />

Conclusion: More than 20 patients received our produced 153 Sm-<br />

EDTMP as a bone pain palliation.<br />

Keywords: 153 Sm, Bone Pain palliation, EDTMP<br />

146

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!